ACADIA Pharmaceuticals to Present at Fifth Annual JMP Securities Healthcare Conference

ACADIA Pharmaceuticals, a biopharmaceutical company focused on developing treatments for central nervous system disorders, will present at the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010, at 8:30 a.m. Eastern Time in New York City. The company's presentation will be webcast live on its website, www.acadia-pharm.com, and an archived recording will be available for two weeks following the event.

Key Takeaways:

• ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to develop novel treatments for central nervous system disorders.
• The company is developing a portfolio of four product candidates, including pimavanserin, which is being developed for three separate indications: Parkinson's disease psychosis, co-therapy for schizophrenia, and Alzheimer's disease psychosis.
• ACADIA has partnerships with Biovail, Allergan, and Meiji Seika Kaisha to develop its product candidates.
• The company's proprietary drug discovery platform has led to the development of several product candidates in various stages of clinical development.

Statistics:

• ACADIA Pharmaceuticals will present at the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010, at 8:30 a.m. Eastern Time.
• The company has a portfolio of four product candidates in development.
• Pimavanserin is being developed for three separate indications: Parkinson's disease psychosis, co-therapy for schizophrenia, and Alzheimer's disease psychosis.
• ACADIA has partnerships with Biovail, Allergan, and Meiji Seika Kaisha to develop its product candidates.

Sources:

• ACADIA Pharmaceuticals Inc. press release, September 2010 (no specific date provided)
• ACADIA Pharmaceuticals Inc. annual report on Form 10-K for the year ended December 31, 2009

Note: The date for the Fifth Annual JMP Securities Healthcare Conference is as stated in the original text.